Current Research Trials
Sydney Retina Clinic and Day Surgery is proud to be associated with a research department named the Sydney Institute of Vision Science. All members of the research team have a strong background in both clinical and laboratory research and are dedicated to the development of new treatment for retinal disease.
In recent months we have been involved in a number of projects, some of which are already completed, and some which are on-going.
AUSSIEDEX (ALLERGAN CMO-AP-EYE-0438)
Phase 4, open-label, non-randomized, prospective study of OZURDEX® in the Treatment of Diabetic Macular Oedema
SEQUOIA (ALLERGAN 150998-006)
Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients With Neovascular Age-related Macular Degeneration
CENTERA (BAYER BAY86-5321/17514)
A multi-center, single-arm, interventional Phase 4 study to evaluate a Treat and Extend regimen of intravitreal aflibercept for treatment of macular edema secondary to central retinal vein occlusion
A randomized, masked, controlled trial to study the safety and efficacy of suprachoroidal CLS-TA in conjunction with intravitreal aflibercept in subjects with central retinal vein occlusion
IONIS (ISIS 696844-CS3)
A Phase 2, Placebo-Controlled, Double-Masked Study to Assess Safety and Efficacy of ISIS 696844, an Antisense Inhibitor of Complement Factor B, in Patients with Geographic Atrophy Secondary to Age Related Macular Degeneration (AMD)
Phase 1b/2a study of OPT-302 in combination with aflibercept for persistent central-involved diabetic macular edema
Investigator Initiated Studies
Clinicopathological Correlation in Macular Degeneration.
Intravitreal Aflibercept for the treatment of treatment resistant retinal vein occlusions.